SK9492002A3 - A complex comprising osteoclastogenesis inhibitory factor and polysaccharide - Google Patents
A complex comprising osteoclastogenesis inhibitory factor and polysaccharide Download PDFInfo
- Publication number
- SK9492002A3 SK9492002A3 SK949-2002A SK9492002A SK9492002A3 SK 9492002 A3 SK9492002 A3 SK 9492002A3 SK 9492002 A SK9492002 A SK 9492002A SK 9492002 A3 SK9492002 A3 SK 9492002A3
- Authority
- SK
- Slovakia
- Prior art keywords
- ocif
- complex
- group
- variants
- substance selected
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001198985 | 2001-06-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
SK9492002A3 true SK9492002A3 (en) | 2003-02-04 |
Family
ID=19036337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK949-2002A SK9492002A3 (en) | 2001-06-29 | 2002-06-28 | A complex comprising osteoclastogenesis inhibitory factor and polysaccharide |
Country Status (22)
Country | Link |
---|---|
US (3) | US20030045456A1 (ru) |
EP (1) | EP1270015A3 (ru) |
KR (1) | KR20030003124A (ru) |
CN (1) | CN1442201A (ru) |
AR (1) | AR034716A1 (ru) |
AU (1) | AU783126B2 (ru) |
BR (1) | BR0202439A (ru) |
CA (1) | CA2392383A1 (ru) |
CO (1) | CO5390084A1 (ru) |
CZ (1) | CZ20022231A3 (ru) |
HK (1) | HK1048762A1 (ru) |
HU (1) | HUP0202119A2 (ru) |
IL (1) | IL150448A0 (ru) |
MX (1) | MXPA02006511A (ru) |
NO (1) | NO20023144L (ru) |
PA (1) | PA8549401A1 (ru) |
PE (1) | PE20030254A1 (ru) |
PL (1) | PL354799A1 (ru) |
RU (1) | RU2232594C2 (ru) |
SG (1) | SG98059A1 (ru) |
SK (1) | SK9492002A3 (ru) |
ZA (1) | ZA200205164B (ru) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
KR20010082272A (ko) | 1998-10-28 | 2001-08-29 | 쇼노 카츄야 | 골대사이상증 치료제 |
EP1270015A3 (en) * | 2001-06-29 | 2004-02-25 | Sankyo Company Limited | A complex comprising OCIF and Polysaccharide |
TW200303757A (en) * | 2002-03-01 | 2003-09-16 | Sankyo Co | A pharmaceutical composition |
AU2003240754B2 (en) | 2002-04-10 | 2009-02-26 | Merck Serono Sa | Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis |
US7585840B2 (en) * | 2002-04-10 | 2009-09-08 | Merck Serono S.A. | Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease |
WO2003103710A1 (ja) * | 2002-06-07 | 2003-12-18 | 三共株式会社 | 骨破壊の治療または予防剤組成物の併用効果 |
KR100840830B1 (ko) * | 2006-09-03 | 2008-06-23 | 재단법인서울대학교산학협력재단 | 고분자 히알루론산을 포함하는 골흡수 저해용 조성물 |
ITMI20121316A1 (it) * | 2012-07-27 | 2014-01-28 | Altergon Sa | Complessi di condroitina ad assorbimento transcutaneo |
CN115594776B (zh) * | 2022-09-19 | 2024-03-15 | 山东大学 | 一种ROS响应性聚合物Mal-PHB-Dextran及细胞背包载药系统 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4207A (en) * | 1845-09-27 | lewis | ||
US181418A (en) * | 1876-08-22 | Improvement in gas apparatus | ||
US31725A (en) * | 1861-03-19 | Improvement in cultivators | ||
US45456A (en) * | 1864-12-13 | Improved apparatus for carbureting air | ||
US216297A (en) * | 1879-06-10 | Improvement in ironing-stands | ||
US139325A (en) * | 1873-05-27 | Improvement in carriage-springs | ||
TW318142B (ru) * | 1991-06-03 | 1997-10-21 | Mitsubishi Chemicals Co Ltd | |
US5464815A (en) * | 1993-09-08 | 1995-11-07 | Genentech, Inc. | Inhibition of heparin-binding |
IL117175A (en) * | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
US6613544B1 (en) * | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
US20030207827A1 (en) * | 1995-12-22 | 2003-11-06 | William J. Boyle | Osteoprotegerin |
US6369027B1 (en) * | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
US6656508B2 (en) * | 1997-04-17 | 2003-12-02 | Amgen Inc. | Sustained-release alginate gels |
NZ335759A (en) * | 1997-09-24 | 2002-02-01 | Sankyo Co | Method of diagnosing metabolic bone diseases by measuring osteoclastgenesis inhibitory factor (OCIF) |
ATE230752T1 (de) * | 1998-06-15 | 2003-01-15 | Takeda Chemical Industries Ltd | Thienodipyridinderivate, ihre herstellung und verwendung |
KR20010082272A (ko) * | 1998-10-28 | 2001-08-29 | 쇼노 카츄야 | 골대사이상증 치료제 |
IL142900A0 (en) * | 1999-09-03 | 2002-04-21 | Amgen Inc | Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
AU2001295850A1 (en) * | 2000-09-28 | 2002-04-08 | Nanocyte Inc. | Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue |
EP1270015A3 (en) * | 2001-06-29 | 2004-02-25 | Sankyo Company Limited | A complex comprising OCIF and Polysaccharide |
TW200303757A (en) * | 2002-03-01 | 2003-09-16 | Sankyo Co | A pharmaceutical composition |
-
2002
- 2002-06-26 EP EP02254497A patent/EP1270015A3/en not_active Withdrawn
- 2002-06-26 CZ CZ20022231A patent/CZ20022231A3/cs unknown
- 2002-06-27 PE PE2002000579A patent/PE20030254A1/es not_active Application Discontinuation
- 2002-06-27 ZA ZA200205164A patent/ZA200205164B/xx unknown
- 2002-06-27 IL IL15044802A patent/IL150448A0/xx unknown
- 2002-06-27 US US10/183,091 patent/US20030045456A1/en not_active Abandoned
- 2002-06-28 PL PL02354799A patent/PL354799A1/xx not_active Application Discontinuation
- 2002-06-28 AU AU50719/02A patent/AU783126B2/en not_active Ceased
- 2002-06-28 SG SG200203944A patent/SG98059A1/en unknown
- 2002-06-28 BR BR0202439-0A patent/BR0202439A/pt not_active IP Right Cessation
- 2002-06-28 NO NO20023144A patent/NO20023144L/no not_active Application Discontinuation
- 2002-06-28 CA CA002392383A patent/CA2392383A1/en not_active Abandoned
- 2002-06-28 PA PA20028549401A patent/PA8549401A1/es unknown
- 2002-06-28 MX MXPA02006511A patent/MXPA02006511A/es unknown
- 2002-06-28 AR ARP020102447A patent/AR034716A1/es unknown
- 2002-06-28 SK SK949-2002A patent/SK9492002A3/sk not_active Application Discontinuation
- 2002-06-28 HU HU0202119A patent/HUP0202119A2/hu unknown
- 2002-06-28 RU RU2002117385/15A patent/RU2232594C2/ru not_active IP Right Cessation
- 2002-06-28 CO CO02056452A patent/CO5390084A1/es unknown
- 2002-06-29 KR KR1020020037598A patent/KR20030003124A/ko not_active Application Discontinuation
- 2002-06-29 CN CN02155849A patent/CN1442201A/zh active Pending
-
2003
- 2003-02-06 HK HK03100851.5A patent/HK1048762A1/zh unknown
- 2003-02-11 US US10/364,045 patent/US20030139325A1/en not_active Abandoned
-
2005
- 2005-10-21 US US11/254,836 patent/US20060084595A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CZ20022231A3 (cs) | 2003-02-12 |
RU2002117385A (ru) | 2004-01-27 |
US20060084595A1 (en) | 2006-04-20 |
EP1270015A2 (en) | 2003-01-02 |
KR20030003124A (ko) | 2003-01-09 |
PL354799A1 (en) | 2002-12-30 |
RU2232594C2 (ru) | 2004-07-20 |
IL150448A0 (en) | 2002-12-01 |
SG98059A1 (en) | 2003-08-20 |
AU5071902A (en) | 2003-01-02 |
ZA200205164B (en) | 2003-03-24 |
HK1048762A1 (zh) | 2003-04-17 |
US20030045456A1 (en) | 2003-03-06 |
PE20030254A1 (es) | 2003-03-19 |
BR0202439A (pt) | 2003-06-10 |
CO5390084A1 (es) | 2004-04-30 |
NO20023144D0 (no) | 2002-06-28 |
CN1442201A (zh) | 2003-09-17 |
EP1270015A3 (en) | 2004-02-25 |
NO20023144L (no) | 2002-12-30 |
CA2392383A1 (en) | 2002-12-29 |
HU0202119D0 (ru) | 2002-08-28 |
HUP0202119A2 (hu) | 2003-04-28 |
AU783126B2 (en) | 2005-09-29 |
PA8549401A1 (es) | 2003-07-28 |
US20030139325A1 (en) | 2003-07-24 |
AR034716A1 (es) | 2004-03-17 |
MXPA02006511A (es) | 2004-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3154566B1 (en) | Actrii antagonist for the treatment or prevention of a cutaneous ulcer in a subject that has anemia | |
US20060084595A1 (en) | Complex comprising OCIF and polysaccharide | |
EP2763689B1 (en) | Fibroblast growth factor 21 variants | |
JP5334347B2 (ja) | 化学的に修飾した新規なエリスロポエチン刺激タンパク質組成物および方法 | |
EP1121155B1 (en) | Site-directed dual pegylation of proteins | |
AU623447B2 (en) | Binding protein for insulin-like growth factors | |
AU2016201712A1 (en) | ActRIIb antagonists and dosing and uses thereof | |
JP2006512326A (ja) | 心臓疾患におけるエリスロポエチンの新規な使用 | |
JP2012530493A (ja) | キメラポリペプチドおよびその使用 | |
AU2014221534B2 (en) | Site-specific insulin conjugate | |
Collier et al. | O-linked oligosaccharides on insulin receptor | |
EP1008603B1 (en) | Soluble polypeptides consisting on the first coiled coil domain of human and mouse epimorphin. | |
JP6464145B2 (ja) | 成長ホルモン化合物製剤 | |
JPH11500904A (ja) | Mplリガンド類似体 | |
US20030216297A1 (en) | Pharmaceutical composition | |
AU691085B2 (en) | Anti-inflammatory CD14 polypeptides | |
AU658187B2 (en) | Human bone derived insulin like growth factor binding protein | |
JP2004203747A (ja) | 破骨細胞形成抑制因子を含有する治療剤 | |
JP2004059582A (ja) | 骨破壊の治療または予防剤組成物の併用効果 | |
CA2368937A1 (en) | Prevention of brain damage in stroke | |
JP2003160601A (ja) | 破骨細胞形成抑制因子を含有する複合体 | |
US6329500B1 (en) | Transforming growth factor-β binding site | |
MXPA01003764A (en) | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility | |
JPH1080277A (ja) | 変異型ヒト成長ホルモンとその用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC9A | Refused patent application |